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Obesity and associated liver diseases (Non Alcoholic Fatty Liver Disease, NAFLD) are
a major public health problem with increasing incidence in Western countries (25%
of the affected population). These complications develop from a fatty liver (steatosis)
to an inflammatory state (steatohepatitis) evolving toward fibrosis and hepatocellular
carcinoma. Lipid accumulation in the liver contributes to hepatocyte cell death and
promotes liver injury. Local immune cells are activated either by Danger Associated
Molecular Patterns (DAMPS) released by dead hepatocytes or by bacterial products
(PAMPS) reaching the liver due to increased intestinal permeability. The resulting
low-grade inflammatory state promotes the progression of liver complications toward
more severe grades. Innate lymphoid cells (ILC) are an heterogeneous family of five
subsets including circulating Natural Killer (NK) cells, ILC1, ILC2, ILC3, and lymphocytes
tissue-inducer cells (LTi). NK cells and tissue-resident ILCs, mainly located at epithelial
surfaces, are prompt to rapidly react to environmental changes to mount appropriate
immune responses. Recent works have demonstrated the interplay between ILCs
subsets and the environment within metabolic active organs such as liver, adipose tissue
and gut during diet-induced obesity leading or not to hepatic abnormalities. Here, we
provide an overview of the newly roles of NK cells and ILC1 in metabolism focusing on
their contribution to the development of NAFLD. We also discuss recent studies that
demonstrate the ability of these two subsets to influence tissue-specific metabolism and
how their function and homeostasis are affected during metabolic disorders.
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INTRODUCTION
Non-alcoholic Fatty Liver Disease (NAFLD) has recently become a pathology of interest as its
increased prevalence is associated with obesity and metabolic syndrome. The spectrum of the
hepatic disease ranges from steatosis (fatty liver) to steatohepatitis (Non-alcoholic Steato-Hepatitis,
NASH) and then the activation of fibrogenic pathways. NASH represents the progressive form
of NAFLD and predisposes to more severe end-stage liver disease such as cirrhosis and/or
hepatocellular carcinoma (Figure 1) (1).
The chronic low-grade inflammation associated with obesity plays an important role in
development and the progression of NAFLD. These hepatic diseases now represent the most
frequent hepatic lesion in western countries (2). Hepatic steatosis is the initial step of the disease
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FIGURE 1 | Spectrum of hepatic abnormalities in NAFLD. During obesity, liver
complications develop from a fatty liver (steatosis) to an inflammatory state
(steatohepatitis) evolving toward fibrosis and hepatocellular carcinoma. NASH,
non-alcoholic steatohepatitis; HCC, hepatocellular carcinoma.
characterized by an influx of lipids coming from inflamed
adipose tissue (AT), increased hepatic de novo lipogenesis and
decreased lipid catabolism. Lipid accumulation in hepatocytes
(free fatty acids, cholesterol. . .) leads to lipotoxicity with
sustained oxidative and endoplasmic reticulum stresses making
them more susceptible to cell death. Liver injury and the
activation/recruitment of inflammatory immune cells promote
disease progression to NASH. The molecular mechanisms
responsible for the progression from a “non-pathogenic” steatotic
state to NASH are still unclear. Despite lifestyle changes, the
treatment of NASH is still limited because of the lack of
effective pharmacological treatment as well as lack of effective
and practical diagnostic tools. Recent findings suggest that
pathogenesis of NASH involves cross talks between liver, gut and
adipose tissue into which the physiology of resident/recruited
immune cells is affected.
The liver is exposed to a variety of harmless (dietary products)
and harmful (pathogens, toxins) particles coming from the
gastrointestinal tract. The liver immune system maintains an
equilibrium between immune surveillance against pathogens
and tolerance to innocuous antigens and commensal bacteria.
This equilibrium is altered during obesity leading to low grade
inflammation that promotes the progression of liver diseases.
Inflammation has thus become a prominent player in the
pathological mechanism of NALFD (3). Obesity is associated
with alterations of the gastrointestinal flora (dysbiosis), increased
gut permeability and afflux of free fatty acids from AT into
the liver. Translocation of bacterial products via the portal vein
triggers low-grade inflammation by acting on innate immune
cells and play an important role in the progression of fatty liver
to an inflammatory state. Hepatic accumulation of lipids is the
hallmark of NAFLD that may influence its progression. Specific
lipid species can cause toxicity promoting hepatocytes death
which in turn release DAMPs that may activate local immune
cells such as macrophages, NK-T cells, and adaptive T cells (4, 5).
Innate lymphoid cells (ILC) are the most recently discovered
family of immune cells that are mainly localized at epithelial
surfaces where theymaintain tissue homeostasis. Their strategical
locations allow them to rapidly respond to pathogen invasion by
mounting appropriate immune responses. ILC are non-T, non-B
lymphocytes that lack antigen receptors encoded by rearranged
genes (6, 7). Similarities between ILC and T cell subsets led to
propose ILC as the innate counterparts of T cell subsets. Even if
many functions of ILC are largely redundant with those provided
by T cells (8), both populations are important coordinators
of the immune response by integrating environmental signals
and by interacting with numerous types of cells (9). A fresh
nomenclature revisits the previous classification of the ILC family
based on cell surface markers, transcription factor requirement
and ability to produce type 1, type 2, and Th17 cell-associated
cytokines and now distinguishes it into five subsets: NK, LTi,
ILC1, ILC2, and ILC3 (10, 11). ILC have been involved in
immune responses against bacteria, virus, parasites, allergens,
and tumor (10–12). The recent progress in the ILC field led to the
identification of new ILC subsets in tissues harboring metabolic
function such as in liver and adipose tissue (13). The interest
in the crosstalk between host metabolic environment and ILC
in specific tissues is growing. How the metabolic changes and
dysbiosis associated with NAFLD impact on ILC differentiation
and functions is still an open question. In this review, we evaluate
the potential role of NK cells and ILC1 in the pathophysiology
of NAFLD.
DEVELOPMENT AND SPECIFIC
PROPERTIES OF ILC1 AND NK CELLS
The five ILC subsets derive from the common lymphoid
progenitor that progresses toward the early innate lymphoid
progenitor in parallel to the upregulation of CXCR6 and the
α4β7 integrin expression (14, 15). The further stage called
common helper ILC precursor contains precursors restricted
to ILC1, ILC2, and ILC3 lineages (16). The position of NK
and LTi lineages along the ILC developmental scheme raised
some controversies with data in favor of a lineage commitment
preceding the acquisition of functions. Notably, the expression of
PLZF transcription factor is a key step in the divergence of these
fates (17, 18).
Conventional NK cells (NK cells) and helper-like ILC1 could
be discriminated by the identity of their T-box transcription
factors. The T-box protein in T cells, Tbet, encoded by the Tbx21
gene is involved in IFN-γ production. Eomesodermin (Eomes)
transcription factor shares homology with Tbet. Mature NK cells
are Tbet+ Eomes+ while ILC1 are Tbet+ Eomes−. In the liver,
Tbet upregulation is induced with ILC1 differentiation (19, 20).
Studies using Eomes reporter mice proved that despite their
immature phenotype, Tbet+ hepatic ILC1 are not precursors of
Eomes+ NK cells (20). ILC1 and NK lineages have been shown to
diverge early in ontogeny (17).
A great diversity was described for NK cells and ILC1 that
differentially expressed a large number of markers depending on
the organ and the activation state (21). Resident ILC1 subsets
have also been defined in multiple organs and are enriched
in liver, gut, uterus, skin and salivary glands (22). An absence
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of commonly conserved unique markers among ILC1 prevents
from a common definition and suggests tissue specific functions.
On top of differential Eomes expression, distinction between
NK cells and ILC1 also concerns their cytotoxic properties
and resident/tropic molecule expression. Relationships between
NK and ILC1 lineages are still fuzzy since distinctive markers
are either not supported in few tissues or after inflammatory
conditions. Indeed, while Eomes expression is restricted to NK
cells in most organs, it could be expressed by salivary gland
ILC1 (23). CD127 is expressed by most ILC despite a disparate
expression among hepatic ILC1 and an absence from those of
the salivary glands. Following activation, NK cells could start
to express CD49a and CXCR6, as ILC1. Hence, transitional
subsets expressing different levels of CD49a and Eomes in case
of inflammation, chronic disease or in tumor, strengthen their
plastic properties (24, 25). Furthermore, the inhibitory receptor
CD200r1 is expressed on the cell surface of peripheral ILC1
(into liver, adipose tissue, small intestine) but not on NK cells
(26). It has been suggested that the combined expression of
CD200r1, Eomes, with CD49b could differentiate ILC1 from
NK cells during homeostasis and viral-induced inflammation
(26). To note, other ILC population such as ILC2 and ILC3 in
the adipose tissue and small intestine also expressed CD200r1
suggesting that CD200r1 may help to discriminate NK cells from
all other ILCs. The mechanisms regulating T-box transcription
factor expression in different organs are mostly unknown. The
Notch signaling pathway can regulate the Tbet/Eomes ratio and
the pro-inflammatory cytokine expression in hepatic NK and
ILC1 subsets (27). Moreover, the ectopic expression of Eomes
in ILC1 induced their conversion toward mature NK cells,
suggesting a role for Eomes in plasticity (28). On the other
hand, NK cells and ILC1 share NKp46, NK1.1, NKG2D, and
CD122 surface makers that were routinely used in most studies
without specific evaluation of the NK/ILC1 input. Both intestinal
and hepatic ILC1, are Eomes−Tbet+NK1.1+ cells requiring
Tbet to develop (16, 20). Contrary to other tissues, liver ILC1
depend on the transcription factor hobit for tissue retention
as tissue resident T lymphocytes (29). On top of a common
CXCR6+CD69+CD49a+ phenotype, hepatic ILC1 also express
molecules important for their tissue location and maintenance
like CXCR3, CD103, CD39 or CX3CR1 (29, 30). The CD49a+
ILC1 population is also currently called tissue-resident NK cells
(trNK cells) and is present in different tissues (skin, intestine,
salivary glands, kidney, uterus, adipose tissue) with striking
phenotypic similarities and some functional differences between
organs that might reflect the impact of microenvironment (31)
or the existence of divers subsets. In particular, liver resident
NK cells/ILC1 expressed higher levels of TRAIL and FasL
with stronger cytotoxic properties than their small intestine
counterpart (32). Contrary to other tissues, hepatic and intestinal
ILC1 are not dependent on IL7 as their total number in both
organs are identical between Il7rα−/− and WT mice (16, 20). In
these organs, ILC1 development depend on IL-15 but not IL-7
as already demonstrated by pionner studies for NK cells (33, 34).
ILC1 express high levels of IL12rβ1 and respond to IL-12 and IL-
15 stimulation by the secretion of IFN-γ and/or TNF-α. IL-18
co-stimulation significantly increases IFN-γ levels (20, 35). The
human CD127+ subset of ILC1 only produce IFN-γ contrary
to its CD127− counterpart producing both TNF-α and IFN-
γ. Human intestinal ILC1 are mostly defined as non-cytotoxic
and could impart Th1 chemoattraction and maturation partly by
CXCR3 expression (36).
NK CELLS AND ILC1 IN ADIPOSE TISSUE
INFLAMMATION IN NAFLD
The AT functions encompass energy storage and endocrine
activities to maintain metabolism homeostasis. The AT is
composed of adipocytes, stromal cells including resident immune
cells and it is now considered as a fully immunocompetent organ.
In the context of obesity, AT hypoxia reflects hypertrophy and
hyperplasia of adipocytes with an impaired insulin signaling,
increased cell death and release of DAMPs. These stress responses
allow the local accumulation and activation of pro-inflammatory
immune cells (M1 macrophages, ILC1, CD4+ Th1, and CD8+
T cells). These cells sustain inflammation and lead to insulin
resistance and metabolic dysregulation (37).
Adipose tissue macrophages (ATMs) represent almost 50% of
the resident AT immune cells and highly contribute to low grade
inflammation and insulin resistance during obesity. Indeed,
ATMs are the dominant source of pro-inflammatory cytokines
(TNF-α, IL-1β). The resulting AT lipolysis increases the rate
of circulating free fatty acids which accumulated into the liver
contributing to hepatic steatosis. The tight control of M2 to M1
transition represents a key event to regulate AT homeostasis
at steady state and during diet-induced obesity (DIO) (1).
Experimental evidences suggested that T-cell subsets have
regulatory potential of M2/M1 balance during obesity. Indeed,
AT infiltrating CD8+ T cells contribute to M1 macrophages
phenotype whereas the decreased number of CD4+ regulatory T
cells fosters AT inflammation in obese subjects (38, 39). Recently,
it has been reported that type 1 innate lymphoid cells (T1-
ILC) also contribute to the homeostasis of ATMs in lean and
obese conditions. The phenotypic and functional heterogeneity
of T1-ILC has been recently investigated in human and mice. All
human lean adipose depots contain T1-ILC ranging from 5 to
10% among resident lymphocytes. In mice, T1-ILC represented
nearly 22 to 30% of AT lymphocytes and constituted the most
abundant lymphocyte population in AT (40, 41). Murine T1-ILC
is composed of helper-like tissue resident ILC1 (mixed Eomes−
CD49a+ CD49b− and Eomes+ CD49a+ CD49b+), immature
(Eomes+ CD49a− CD49b−) and circulating mature NK cells
(Eomes+ CD49a− CD49b+) and human AT is composed of
two populations CD56dim CD16− and CD56dim CD16+ T1-
ILC1. High fat diet (HFD) challenge increases both ILC1 number
and activation in AT and are the major source of IFN-γ, TNF-
α. In turn, ILC1 enable ATMs-M1 polarization leading to AT
inflammation and insulin resistance (40, 42, 43). Moreover, T1-
ILC depletion ablation in DIO mouse model was associated
with decreased macrophage infiltration, M1 polarization and
insulin resistance (42–44). Boulenouar et al. reported that all
the three T1-ILC (CD49a+ mixed ILC1, iNK cell, and mNK
cell subsets) are able to preferentially kill M2 macrophages in
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lean conditions but have impaired cytotoxicity with obesity that
may explain an increase in M2 conversion/polarization into M1
macrophages with obesity (41). Furthermore, ILC1 produce the
macrophage chemoattractant CCL2 and ATMs increase their
NK cell chemoattractant production such as CCL3, CCL4, and
CXCL10 (43). While the upstream signals leading to obesity-
associated inflammation remains to be fully defined, IL-12 was
suggested as a driver of ILC1 accumulation and activation in
AT (40). Therefore, the T1-ILC/-macrophage cross-talk is a
key regulator of AT inflammation representing a promising
therapeutic target for treating patients with metabolic syndrome
and NAFLD.
NK CELLS AND ILC1 IN GUT FUNCTIONS
IN NAFLD
The close anatomical proximity of the gastrointestinal tract and
the liver creates a functional link between these two organs. The
portal venous system drains intestinal nutrients and products to
the liver. During obesity, gut dysbiosis with increased intestinal
permeability contribute to the development and progression of
NAFLD in mouse and human (45, 46). Murine intestinal ILC1
encompassed intraepithelial ILC1 (CD49a+ Eomes+) and lamina
propria-resident ILC1 (CD49a+ CD127+ Eomes−) which are
distinct from conventional lamina propria NK cells (CD49a−
Eomes+ CD127−) (47). The intestinal ILC1 population is more
complex that initially supposed. By using RORγt-fate map (fm)
mice, Klose et al. identified a small fraction of Lin− NKp46+
NK1.1+ intestinal cells (20%) originated from the ILC3 lineage,
now referred to ILC1 “ex-RORγt ILC3” (16). The plasticity
observed between ILC1 and ILC3 lineages was studied using
mouse genetic lineage-tracking experiments and human ex-vivo
intestinal cell cultures (48–50). Both small intestinal NK cells
and NKp46+ ILC3 are activated after oral Listeria monocytogenes
infection. However, only NK-derived IFN-γ contributes to limit
bacterial dissemination while IL-22 produced by NKp46+ ILC3
appeared dispensable (51). Moreover, ILC1 have been reported
as the dominant innate source of IFN-γ and TNF-α in mice
infected with the Toxoplasma gondii whereas NK cells and ILC3
contributed to a lesser extent (16). Aryl Hydrocarbon Receptor
(AHR) ligands that can either derived from diet or microbiota
are important sensors of the intestinal immune cells and regulate
ILC development and NK cell functions (52, 53).
Intestinal microbial manipulation has been recently
proposed for the management and treatment of NAFLD.
The administration of pro/prebiotics allows the reduction of
intestinal permeability and inflammation (54). The Short-chain
fatty acids (SCFAs), products of the fermentation of dietary fibers
by the anaerobic intestinal microbiota, have beneficial effects on
mammalian energy metabolism and foster anti-inflammatory
immune responses. The SCFAs acetate, propionate, and butyrate
are found in the intestinal tract and may cross the gut barrier to
reach the liver through the portal vein blood (55). In addition,
SCFAs could signal via FFAR3+ (GPR41) and FFAR2+ (GPR43)
receptors in immune cells. Propionate and butyrate were
described to attenuate pathogenic allergic Th2 responses by
controlling DC hematopoiesis (56). Furthermore, SCFAs also
enhanced protective CD8T cell responses against flu infection
and reduced neutrophil recruitment into the lung (57). Similarly,
acetate has been shown to improve recall function of memory
CD8+ T cells (58). Whether such metabolites regulate intestinal
or liver NK cells and ILC1 functions is still an open question
that could be addressed to propose new therapeutic approaches
in NAFLD.
HEPATIC NK CELLS AND ILC1 IN NAFLD
DEVELOPMENT
The liver is mainly composed of hepatocytes (80% of liver cells)
and non-parenchymal cells which include immune, endothelial,
stellate and biliary cells. Liver NKp46+ cells account for
approximately 10%-20% of total intrahepatic lymphocytes in
mouse and almost 40–50% in human. In mice, liver NK cells
are Eomes+ CD49b+ CD49a− TRAIL+/− while liver ILC1 are
Eomes− CD49b− CD49a+ TRAIL+ (59, 60). Murine liver ILC1
have the potent ability to produce cytokines (IFN-γ, TNF-α,
IL-2, GM-CSF) (20). It has been reported that mouse hepatic
CD49a+ILC1 residing in the liver sinusoids contribute to the
response against virus, haptens antigens and are endowed with
memory properties (20, 61, 62).In human liver, the CD45+ Lin−
CD16− NKG2A− CD127+ CD161+ ILC population regroups
CRTH2+ ILC2, ILC1, and NKp44− ILC3 and NKp44+ ILC3
and is distinct from hepatic CD16+ or NKG2A+ NK cells (63).
Moreover, equal proportion of liver CD56bright and CD56dim
NK cells have been described among the total human liver NK
cell population contrary to blood where the CD56dim subset
represents at least 90% of all peripheral blood NK cells. The liver
CD56bright population expresses Eomes but low levels of T-bet
that should identify this population as conventional NK cells
based on mouse studies. However, human hepatic CD56bright
expresses “tissue residency” markers such as CD69 and CXCR6
and thus are more similar to mouse ILC1/tr NK cells (64–66).
Among the CD56bright subset in the liver, a rare fraction (2.3%)
are Eomes− T-bet+ and expresses CD49a producing high levels
of IFN-γ, TNF-α and GM-CSF (67). This small subset of liver
CD56bright CD49a+ cells represent a putative human counterpart
to mouse hepatic CD49a+ ILC1/tr NK cells.
NK cells are involved in protective immune responses against
hepatitis B and C virus infection or in limiting liver fibrosis and
hepatocellular carcinoma (68). It is obvious that liver NK cells
via TRAIL and/or NKG2D signaling have a major role in the
removal of activated hepatic stellate cells in fibrotic liver or liver
cancerous cells as reported in a tetrachloride mouse model of
hepatic fibrosis (69, 70).We cannot rule out the contribution liver
resident ILC1 in these earlier studies via either cytokine secretion
or TRAIL-induced killing of target cells as recently described
for activated NK cells (71). Hence, specific host protective roles
are assigned to ILC during immune response. Hepatic ILC1
could contribute to the pathogenesis of chronic hepatitis B
via pro-inflammatory cytokine production. ILC1 could then
regulate cell responses against virus and intracellular bacteria
(20, 72, 73). In that sense, Weizman et al. recently demonstrated
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that conventional liver resident XCR1+ dendritic cells produce
IL-12 after MCMV infection which in turn promotes ILC1
production of IFN-γ (26). Inflammation is a major contributor
of diet-induced liver complications. IL-15 is a pro-inflammatory
cytokine essential for the homeostasis of NK cells but also NK-
T cells, γδ T cells and memory CD8T cells. IL-15 deficient
mice are protected from obesity-associated metabolic disorders
upon HFD challenge. IL-15 is involved in diet-induced lipid
accumulation and hepatic inflammation (74). IL-15 decreases
the hepatic expression of the fatty-acid oxidation transcription
factor PPARα and promotes the lipid intake by regulating
CD36 expression. IL-15 may also increase the pro-steatotic
transcription factor PPARγ expression. IL-15 is a key cytokine
for innate immune cells homeostasis during the development of
hepatic steatosis. Therefore, we can speculate that the metabolic
effect of IL-15 may be partly due to hepatic NK cell and/or
ILC1 activities. Furthermore, a gene expression pattern of
inflammatory markers such as IFN-γ, TNF-α, IL-18, CCL5,
CXCL10 are upregulated in the NASH liver of morbidly obese
patients compared to lean subjects that could be produced and/or
could regulate type 1 ILC behavior (75, 76). IL-1α and IL-18
have been implicated in the transformation frommurine steatosis
to steatohepatitis (77). Adipokines (adiponectin, Ghrelin, and
leptin) levels have been correlated to insulin resistance and their
decrease could promote NAFLD evolution (78). It should be
determined whether these adipokines could directly interact with
NK/ILC1 subsets. Interestingly, hepatic osteopontin (OPN) gene
expression is increased and is related to the severity of hepatic
steatosis (79). OPN has been described as a chemotactic factor
for dendritic cells, macrophages and regulates the lymphocyte
phenotype (Th1 and Th17) (80, 81). It could be of interest to
evaluate the contribution of OPN on liver type 1 ILC function
as it is known that OPN promotes NK cell development and
regulates NK cell homeostasis and functions (82, 83). However,
it is needed to first identify which liver cells produce OPN during
NAFLD development and whether liver type 1 ILC could respond
to OPN to ascertain that OPN could be a new actor in the
regulation of liver type 1 ILC functions.
Myeloid and ILC1/NK cells are able to influence their
effector functions by cell-cell contact and/or via cytokine
production (26, 84, 85). In NAFLD, experimental evidences
have shown that conversion of macrophage toward a pro-
inflammatory phenotype contributes to disease severity (86,
87). Liver macrophages activation is mediated by translocated
bacterial products due to intestinal permeability and also by
the regulation of M1/M2 ratio. Indeed, In a murine model
of steatohepatitis (methionine and choline deficient diet), IFN-
γ-producing NK cells polarize macrophages toward M1 and
NK cell depletion prevent fibrogenesis (88). In this mouse
model, activated liver CD49b+ NK cells are increased whereas
liver CD49a+ ILC1 are decreased suggesting a finely tuned
interplay between these subsets. However, the elimination
of NKp46+ cells required numerous injections of diphteria
toxin, possibly generating local inflammation and macrophage
FIGURE 2 | Type 1 ILC during obesity-induced liver inflammation. Obesity is associated with adipose tissue dysfunction, increased gut permeability and dysbiosis.
These alterations are responsible for the release of bacterial products, the increase in endotoxin levels, the afflux of free fatty acids in the portal circulation as well the
increase of de novo lipogenesis. These extra hepatic actors participate in the establishment of hepatic low grade inflammation. This leads to the activation of innate
immune cells (group 1 ILC, dendritic cells, macrophages) and maintain the process of hepatic inflammation, via the production of inflammatory cytokines. All these
events lead to a vicious cycle that aggravates liver injury, increases inflammation and thus promotes progression to more severe stages of the disease. Rae-1, retinoic
acid early inductible−1; TRAIL, TNF-related apoptosis-inducing ligand; PPAR, peroxisome proliferator-activated receptor; Cpt1a, Carnitine Palmitoyltransferase 1a;
NEFA, Non esterified fatty acid; FFA, Free fatty Acid; ILC, Innate Lymphoid Cells.
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cell death. Finally, type 1 ILC represent a major innate cell
population in the liver and their ability to respond to various
signals (stressed cells expressing NK receptor ligands, death
receptors, IL-12/IL-18 cytokines, CCL5, CXCL10 chemokines. . .)
and to interact with macrophages allow them to be a
credible candidate involved in the development and severity of
NAFLD (Figure 2).
METABOLIC ACTIVITIES OF NK CELLS
To improve therapeutic strategies against cancer or microbial
infections, efforts have recently been made to decipher
metabolism regulation of immune cell functions. The basal
activity of the metabolic checkpoint kinase mTOR (mammalian
target of rapamycin) was shown to correlate with NK cell
responsiveness and be enhanced upon IL-2 and IL-15 stimulation
(89, 90). These studies pointed out the key role of mTOR
signaling in the regulation of NK cell differentiation, granzyme
B expression and IFN-γ production (91, 92). In addition,
cytokine-stimulated NK cells upregulate the expression of Srebp
1/2 (Sterol-regulatory-element-binding proteins) target genes
involved in cholesterol and fatty-acid metabolism (93). While
lipid synthesis was not crucial for NK cell functions, Srepb
unexpectedly regulated glucose metabolism which is critical for
NK cell cytotoxicity and IFN-γ production. Therefore, mTOR
and Srebp pathways may represent new targets to modulate NK
cell functions. In addition, a recent report suggests a link between
NK cell activity, mTOR, and OPN (83). OPN-KO NK cells
harbored defective response to IL-15 with impaired upregulation
of mTOR activity associated with defective NK cell development
and functions. This phenotype is similar to mTOR deficient
NK cells as shown by Marcais et al. (89). These results identify
OPN as an intermediate in the IL-15 pathway that may regulate
NK cell homeostasis and function through interactions with the
mTOR pathway.
It is now well-established that obesity is associated with an
increased risk of cancer and infections (94, 95). Recent evidences
suggest that the impaired immunosurveillance observed in obese
patients may be partly due to altered function of NK cells (91, 96).
Peripheral blood NK cells from obese individuals displayed an
activated phenotype and were hypo-responsive to stimulation
in vitro. This exhausted phenotype highly correlated with body
mass index and could explain the enhanced susceptibility of obese
individuals to develop immune-related diseases such as cancers
and infections (91). Recently, Michelet et al. demonstrated that
the blunted anti-tumor response of NK cells during obesity
is caused by the lipid accumulation in NK cells in a PPAR-
dependent inhibition of the mTOR pathway (96). However,
authors focused on spleen and blood NK cells without evaluating
their tissue counterparts such as AT, intestine and liver, whose
environmental changes are mostly impacted with obesity. How
these changes affect the functions of tissue-specific ILC and
regulate their cell-intrinsic metabolic pathways need to be
addressed to better understand the mechanisms involved in
NAFLD and therefore find new therapeutic targets.
CONCLUSION
Here, we evaluated the contribution of NK cells and helper-
like ILC1 in the setting of liver inflammation during NAFLD
progression. Data highlight the contribution of adipose tissue
and gut NK cells and ILC1 in the control of local inflammation
and/or dysbiosis during obesity which in turn may contribute to
the evolution of hepatic abnormalities. How metabolic changes
associated with NASH progression impact ILC differentiation is
still an open question. Further analyses are required to evaluate
the effect of lipids and altered microbiota on tissue-resident ILC1
and NK cell function in targeted tissue during obesity. This will
help to better appreciate the contribution of NK cells and ILC1 in
the physiopathology of NAFLD.
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